[Webinar] Enterprise R&D Transformation Case Studies: Biogen and Sanofi

Discover how a modern, cloud-native informatics platform can help life sciences firms achieve enterprise-grade R&D efficiency

Sign up for this webinar to find out how Biogen and Sanofi transformed their R&D in these enterprise transformation case studies

We respect your privacy, by clicking ‘Watch On Demand’ you agree to receive our e-newsletter, including information on Podcasts, Webinars, event discounts and online learning opportunities. For further information on how we process and monitor your personal data click here. You can unsubscribe at anytime.

This FREE webinar was recorded on:
10 November, 2021
09:00 AM - 10:00 AM EST

As global biotechnology R&D organizations modernize their digital applications in order to drive data management, collaboration and process efficiency, they are finding that decades of legacy infrastructure and customizations are creating barriers to meaningful change.

In this webinar, guest speakers from Biogen and Sanofi will share their success stories of moving away from their legacy software and upgrading to new solutions that drive R&D transformations throughout their organizations.

Find out how by implementing just one R&D data management solution, pharma firms can carry forward insights and workflows into more structured and controlled development processes, offering them potential competitive advantages.

Join this webinar to discover:

  • How legacy applications can lead to additional costs and lost opportunity over time
  • Why usability and collaboration are key considerations in R&D transformation
  • Case studies on how Biogen and Sanofi led successful changes across their R&D teams to improve productivity and output

Presenters

Ayman Ismail
Principal Scientist – Lab Head
Sanofi

Ayman Ismail holds a PhD in Molecular Biophysics. In his role as Principal Scientist – Lab Head at Sanofi, he leads biologics-based therapeutic discovery projects. He also manages a protein production and characterization group supporting the entire Rare and Neurologic Disease research department. Ismail was responsible for Benchling deployment at Bioverativ in 2017. After Sanofi’s acquisition of Bioverativ, he played a crucial role in Sanofi’s decision to transition to Benchling.

David Sexton
Senior Director Genome Technologies and Informatics
Biogen

David Sexton is Biogen's Senior Director of Genome Technology and Informatics and handles all NGS sequencing, NGS data analysis and information systems. Sexton has more than 25 years of experience in genomics and informatics and was the Head of Genome Informatics at NIBR where he focused on data architecture and infrastructure for genomics data. He is deeply involved in the FAIR data community, has worked in both BioPharma and academia, and is a member of the Pistoia Alliance's steering committee, UK Biobank and FinnGen. He currently leads a data infrastructure change at Biogen to help data scientists find and access research data for meta-analysis and empower bench scientists to query and view data relevant to their work.

Loren Perelman
Head of Enterprise Professional Services
Benchling

Loren Perelman spent much of his career focused on helping organizations make better use of their primary asset, data, by improving methods of collection and utilization. Prior to Benchling, Perelman was Vice-President of Scientific Solutions at Riffyn, working with various customers in the biotech and biopharma spaces. Before Riffyn, he spent more than a decade leading the R&D, PD and manufacturing teams in the same spaces, with a focus on quality, analytical chemistry and stats/modeling. His education includes a PhD in Materials Science from UCSD and a B.S. in Chemistry from Harvey Mudd College.

Sponsor


We respect your privacy, by clicking ‘Watch On Demand’ you agree to receive our e-newsletter, including information on Podcasts, Webinars, event discounts and online learning opportunities. For further information on how we process and monitor your personal data click here. You can unsubscribe at anytime.